While the contribution of PAR2 in ovarian cancer has been previously shown [27,28,29], we now present evidence demonstrating the prevailing role of Pc(4-4) directed toward PAR2-PH binding domain as a therapy treatment in ovarian cancer. This evidence concerns the gene F2RL1 and ovarian carcinoma.